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Head to head: should the intraductal component of invasive prostate cancer be graded?
The reporting of intraductal carcinoma of the prostate
(IDCP) is controversial, with conflicting recommenda-
tions having recently been published by the Interna-
tional Society of Urological Pathology (ISUP) and the
Genitourinary Pathology Society (GUPS). Both recom-
mend that isolated (pure) IDCP should not be graded.
However, the ISUP recommends incorporating the
IDCP component of invasive prostate cancer in the
Gleason score, whereas the GUPS recommends report-
ing IDCP as a comment, independently of the Gleason
score. The arguments for and against incorporating
the IDCP component of invasive prostate cancer in
the Gleason score are discussed in detail.
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Introduction
Intraductal carcinoma of the prostate (IDCP) is char-
acterised by a lumen-spanning proliferation of atypi-
cal epithelium within expanded pre-existing prostatic
ducts, with, at least, a partially preserved basal cell
layer. IDCP was identified as a distinct entity in
1985,1 and diagnostic criteria were described by
McNeal et al. in 1996.2 However, it gained more
widespread recognition in 2006 following a report of
prostate needle biopsies containing only IDCP by Guo
and Epstein, who established the criteria for the diag-
nosis of IDCP, to be used especially on needle biop-
sies.3 Following a decade of extensive discussion in
academic circles, IDCP was formally recognised as a
biologically distinct entity in the 2016 edition of the
World Health Organization classification of tumours
of the prostate gland.4 This development and the
concurrent publication of the recommendations of the
International Society of Urological Pathology (ISUP)
consensus conference on Gleason grading5 has led to
more widespread recognition of this entity by practis-
ing pathologists.
Recently, two international organisations, the ISUP
and the Genitourinary Pathology Society (GUPS),
have published independent updates on prostate can-
cer grading.6,7 Unfortunately, these have conflicting
recommendations on the reporting of IDCP. Both rec-
ommend that isolated (pure) IDCP should not be
graded. However, the ISUP recommends incorporat-
ing the IDCP component of invasive prostate cancer
in the Gleason score (GS), whereas the GUPS recom-
mends reporting IDCP as a comment, independently
of the GS. Thus, a tumour with GS 4 + 3 and come-
donecrosis IDCP would be reported as GS 4 + 5 = 9
according to the ISUP recommendations, but as GS
4 + 3 = 7 (comedonecrosis IDCP) according to the
GUPS recommendations. This potentially confusing
situation for pathologists and clinicians will make it
difficult to render comparisons of prostate cancer
cohorts graded according to different rules.
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We describe the rationales behind the contradictory
ISUP and GUPS recommendations for reporting of
IDCP associated with invasive prostate cancer. The
views expressed in this article are personal opinions
of the authors, and do not necessarily represent those
of the ISUP or the GUPS.
Yes: the IDCP component of invasive
prostate cancer should be incorporated in
the GS (Murali Varma)
There are several scientific and practical arguments
in favour of incorporating the IDCP component of
invasive prostate cancer (IDCP-invasive) in the GS.
T H E G L E A S O N G R A D I N G S Y S T E M I S B A S E D O N
M O R P H O L O G Y
The scientific basis of Gleason grading remains the
morphological examination of prostate cancer. All
historical and contemporary Gleason outcome data
are based on morphology without immunohistochem-
ical examination to identify IDCP. As IDCP was not
recorded as a separate prognostic factor in these stud-
ies, it is safe to assume that they had incorporated
IDCP-invasive in the GS. Thus, comedonecrosis IDCP-
invasive would have been graded as Gleason pattern
5 in these studies. Changing the established grading
method would require evidence that the new
approach is superior.
T H E R E I S N O E V I D E N C E T H A T E X C L U D I N G I D C P
F R O M T H E G S I M P R O V E S P R O G N O S T I C A T I O N
There are no outcome data indicating that IDCP-in-
vasive has a better prognosis than the corresponding
Gleason pattern. Khani and Epstein described three
cases of biopsy GS 3 + 3 = 6 prostate cancer associ-
ated with IDCP-invasive in which no higher-grade
invasive component was identified in corresponding
prostatectomy specimens.8 However, these prostatec-
tomy specimens had been only partially submitted for
histological examination, precluding exclusion of
unsampled higher-grade cancer. In contrast, several
studies have reported that IDCP-invasive is generally
associated with aggressive prostate cancer.9 The clini-
copathological outcome of biopsy GS 3 + 3 = 6 inva-
sive cancer associated with IDCP-invasive in the
Khani and Epstein series was very different from that
of biopsy GS 3 + 3 = 6, with 20% of patients show-
ing disease progression, 13% developing metastases,
and 7% suffering from prostate cancer mortality.8
Hence, prostate cancer grading would be less predic-
tive of outcome if IDCP-invasive were to be excluded
from the GS.
R E P O R T I N G G U I D E L I N E S M U S T N O T B E B A S E D O N
R A R E S C E N A R I O S
Although IDCP may rarely represent a precursor
lesion, there is consensus that it generally represents
invasive prostate cancer extending into pre-existing
benign ducts/acini. Hence, in most cases, it will be
invasive carcinoma that is being graded if IDCP-inva-
sive in needle biopsies is incorporated in the GS. The
biopsy GS provides an imperfect reflection of the true
GS in the prostate gland, owing to the intrinsic sam-
pling error of this technique,10 so clinical practice
should be based on the more common scenario. In
the rare scenario of GS 3 + 3 = 6 with cribriform
IDCP-invasive, the case should be assigned GS 7 with
an explanatory comment.
T H E R E I S N O I N T E R N A T I O N A L C O N S E N S U S O N
E X C L U D I N G I D C P - I N V A S I V E F R O M T H E G S
IDCP is often discussed as a single entity, whereas it
actually represents two biologically distinct entities
requiring different reporting rules. IDCP-invasive is
analogous to prostatic intraepithelial neoplasia (PIN)-
like adenocarcinoma, which has the morphology of
high-grade PIN but is a growth pattern of invasive
prostate cancer. Hence, it would be appropriate to
incorporate IDCP-invasive in the GS while not grad-
ing pure (precursor-type) IDCP. The 2014 ISUP con-
sensus meeting on Gleason grading addressed only
issues related to pure (isolated) IDCP. Grading of
IDCP-invasive was not discussed or voted on in this
meeting. The related publication states only that
‘IDC-P without invasive carcinoma should not be
assigned a Gleason grade’.5 Thus, there is no interna-
tional consensus regarding the grading of IDCP-inva-
sive.
E S T A B L I S H E D I D C P C R I T E R I A M A Y B E T O O
S T R I N G E N T F O R I D C P - I N V A S I V E
The widely used criteria for the diagnosis of IDCP are
those described by Guo and Epstein.3 These criteria
were established to identify patients with isolated
(pure) IDCP in prostate biopsies who would be suit-
able for radical therapy even in the absence of an
identified invasive component. Hence, the bar has
been set very high to avoid overtreatment, and these
criteria may be too restrictive for the diagnosis of
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IDCP-invasive. Several studies have demonstrated
that invasive prostate cancer associated with loose
cribriform proliferations lacking necrosis and severe
nuclear atypia has an outcome comparable to that of
IDCP-invasive.11,12 Grading based on architecture
would ensure that this component is categorised as
Gleason pattern 4, whereas describing this compo-
nent separately as ‘atypical intraductal proliferation’
would risk undergrading and undertreatment
(Figure 1).
I M M U N O H I S T O C H E M I S T R Y C A N N O T E X C L U D E
I D C P - I N V A S I V E
Exclusion of IDCP-invasive from the GS would require
accurate and reproducible identification of IDCP, but
an interobserver reproducibility study of 39 interna-
tional experts found significant variation in the mor-
phological diagnosis of IDCP.13 It is often challenging
to accurately identify basal cells on routine examina-
tion, and definitive distinction of IDCP from invasive
carcinoma would require immunohistochemistry. How-
ever, although basal cell marker immunoreactivity
would support a diagnosis of IDCP, the absence of basal
cells would not exclude IDCP. The basal cell layer is
often very fragmented in expanded ducts of IDCP, and
basal cells may be absent in the immunostained level
(Figure 2). Thus, distinction of IDCP-invasive from
invasive carcinoma may not be possible even with the
use of immunohistochemistry. Variable interpretation
of immunohistochemical findings could also aggravate
the variation in IDCP reporting, even among experts.
When a focus showed some comedonecrosis glands
with basal cells and others without basal cells, Fine
et al.14 interpreted the focus as a combination of IDCP
and invasive cancer, whereas Madan et al.15 would
interpret the entire focus as IDCP-invasive.
Q U E S T I O N I N G T H E G R A D I N G O F C O M E D O N E C R O S I S
I D C P I S A S K I N G T H E W R O N G Q U E S T I O N
It has been argued that it would be inappropriate to
grade comedonecrosis IDCP-invasive associated with
low-grade cancer, as there is no evidence that such
patients have an adverse outcome.14 However, such
cases are rare, and it should be noted that there is
also no evidence that patients with low-grade cancers
associated with only focal comedonecrosis foci lacking
basal cells have a worse outcome. Moreover, it will
not be possible (particularly in needle biopsies) to
exclude the possibility that the ‘invasive come-
donecrosis Gleason pattern 5’ focus represents IDCP
with basal cells that were not represented in the
plane of section. It may be more reasonable to ques-
tion whether comedonecrosis should be graded as
Gleason pattern 5 (irrespective of the presence or
absence of basal cells) rather than inconsistently
grading some foci but not others.
In addition to the theoretical issues elucidated
above, there are logistical issues with excluding
IDCP-invasive from the GS.
V A R I A B L E U T I L I S A T I O N O F
I M M U N O H I S T O C H E M I S T R Y I M P A C T S O N I D C P
R E C O G N I T I O N
There is significant variation in the utilisation of
basal cell marker immunohistochemistry. Whereas
A B
Figure 1. This focus (A), which was associated with invasive Gleason pattern 3 prostate cancer elsewhere in the biopsy (not illustrated), is
morphologically consistent with cribriform Gleason pattern 4 but shows patchy basal cell marker immunoreactivity (B). The absence of
comedonecrosis and marked nuclear enlargement in this loose cribriform proliferation precludes a diagnosis of intraductal carcinoma of the
prostate. If grading were not based on morphology, then this case would have to be reported as Gleason score 3 + 3 prostatic adenocarci-
noma with an associated atypical cribriform proliferation, which could result in undertreatment. (A, haematoxylin and eosin; B, p63.).
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immunohistochemistry is used liberally in some insti-
tutions, others use it more sparingly or have limited
access to this technique. International grading guide-
lines must be suitable for a variety of healthcare sys-
tems. Basing the GS on immunohistochemical
findings risks rendering global comparisons of GS
data meaningless. For example, a prostate biopsy
with GS 4 + 3 invasive cancer and focal come-
donecrosis would be graded as GS 4 + 5 = 9 by some
pathologists, on the basis of morphology, whereas
others would grade it as GS 4 + 3 = 7 associated
with IDCP after immunohistochemical examination.
E X P E R T G S A S S I G N M E N T S H O U L D N O T B E B A S E D
O N N O N - E X P E R T P R A C T I C E
Most experts in a recent survey indicated that they
would generally assign the GS on the basis of mor-
phological identification of IDCP, but would exclude
from the GS an IDCP component identified following
immunohistochemistry performed by a referring non-
expert pathologist.16 This could result in a case being
graded differently by an expert according to whether
the expert is the reporting or reviewing pathologist.
Grading based on architecture would be more repro-
ducible.
A N I D C P C O M M E N T M A Y N O T B E A C T E D U P O N
The presence and significance of IDCP-invasive could
be conveyed as a separate note, but this approach
carries significant risk, as clinicians may disregard
this information. Khani and Epstein reported that 11
(18%) patients with GS 3 + 3 = 6 plus IDCP-invasive
were inappropriately managed by active surveillance,
despite the reports including a note highlighting the
association of IDCP with unsampled high-grade can-
cer.8 The situation is likely to be worse in less devel-
oped healthcare systems, where the implication of
IDCP is less likely to be appreciated by the pathologist
and treating clinician. Most cancer registries do not
record the presence of IDCP, so this critical prognostic
information could be lost if not incorporated in the
GS. Finally, IDCP is not part of most prognostic
nomograms used to manage prostate cancer patients.
It is noteworthy that similar arguments were used in
the ISUP 2005 guidelines to recommend incorporat-
ing a minor component of higher-grade pattern in
the biopsy GS rather than conveying this information
in an accompanying note.17
P E R C E N T A G E O F G L E A S O N P A T T E R N 4 R E P O R T I N G
I S S I M P L E R I F I D C P - I N V A S I V E I S I N C O R P O R A T E D
I N T H E G S
All international guidelines (GUPS, ISUP, and WHO)
recommend reporting the percentage of Gleason pat-
tern 4 in GS 7 tumours. Exclusion of cribriform IDCP-
invasive from the GS would require its distinction
from invasive cancer, which can be impossible with-
out immunohistochemistry. The GUPS recommends
performing immunohistochemistry only in cases in
which the distinction would affect GS assignment.
However, this recommendation could be confusing,
particularly for general pathologists. For example, in
many biopsies with prostate cancer that is morpho-
logically GS 4 + 3 = 7, they would have to determine
whether some of the cribriform component could rep-
resent IDCP, and then assess whether the GS would
be altered by exclusion of this component.
A B
Figure 2. Gleason pattern 3 adenocarcinoma associated with cribriform glandular proliferation showing patchy basal cell marker (BCM)
immunoreactivity, in keeping with intraductal carcinoma of the prostate (IDCP). The few cribriform glands lacking BCM immunoreactivity
(arrow) are morphologically similar to adjacent cribriform glands with patchy BCM immunoreactivity, suggesting that these represent IDCP
rather than invasive cancer. (A, haematoxylin and eosin; B, cytokeratin 5/6.). [Colour figure can be viewed at wileyonlinelibrary.com]
© 2020 The Authors. Histopathology published by John Wiley & Sons Ltd, Histopathology, 78, 231–239.
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International guidelines should not complicate
pathology reporting unless there is clear evidence
that the recommended practice has clinical utility.
There is currently no evidence that the biological sig-
nificance of cribriform IDCP-invasive differs from that
of cribriform invasive prostate cancer.
I N C O N S I S T E N T R U L E S F O R I N C L U S I O N O F I D C P I N
T U M O U R G R A D E A N D E X T E N T
Many expert urological pathologists currently incor-
porate IDCP-invasive in the determination of tumour
extent but not in the GS.16 It would be more consis-
tent to include IDCP-invasive in both prognostic indi-
cators.
In the absence of evidence that the outcome of
IDCP-invasive identified by immunohistochemistry is
different from that of IDCP-invasive identified by mor-
phology-based grading, it would be scientifically
appropriate, simpler and more reproducible to convey
the adverse prognostic significance of IDCP-invasive
by incorporating it in the GS. This would ensure cor-
rect prognostication for most patients, particularly in
prostate needle biopsies. Excluding IDCP-invasive
from the GS would require greater use of sometimes
limited immunohistochemical resources, and risk a
significant number of patients being undertreated. For
identification of IDCP-invasive to be based predomi-
nantly on morphology, evidence that generalists can
reliably identify basal cells on haematoxylin and eosin
(H&E)-stained sections would be required.
No: the IDCP component of invasive
prostate cancer should be reported
independently of the GS (Jonathan Epstein)
N O T A L L I D C P S R E P R E S E N T T H E I N T R A D U C T A L
S P R E A D O F H I G H - G R A D E I N V A S I V E C A R C I N O M A
There are two different biological pathways in the
development of IDCP. The majority of IDCPs are asso-
ciated with invasive high-grade adenocarcinoma, and
the IDCP is believed to represent retrograde intraduc-
tal spread of the invasive adenocarcinoma. However,
a small subset of IDCPs are not associated with inva-
sive high-grade adenocarcinoma, and appear to rep-
resent precursor lesions of prostate cancer.18
It would be problematic to grade IDCP as Gleason
pattern 4 or 5 cancer in the small subset of cases
that show only a low-grade (Grade Group 1) prostate
cancer or no evidence of invasive cancer.8,19
Although these scenarios are very uncommon, grad-
ing rules should apply to all cases and not result in
erroneous grades even in a minority of patients for
whom it would significantly adversely impact on
prognosis and treatment. IDCPs with no invasive can-
cer or only low-grade invasive cancer probably repre-
sent precursor lesions that have significantly better
prognostic characteristics than the more common
IDCPs admixed with invasive high-grade cancer.18
I have seen several entirely embedded radical prosta-
tectomy specimens with IDCP with necrosis that
either lacked invasive cancer or only had associated
focal GS 3 + 3 = 6 (Grade Group 1), and for which
extensive immunohistochemical studies ruled out
invasive high-grade cancer (Figures 3 and 4). In
these cases, if IDCP had been graded, the grade would
have been GS 4 + 5 = 9, which would have been
inaccurate, as their prognosis should be excellent in
the absence of either any invasive cancer or only
focal low-grade cancer. In addition, if the IDCP had
been graded, these patients could have received
unnecessary potentially morbid adjuvant therapy.
Grouping IDCP and prostate cancer together will also
increase the likelihood that pathologists will not
report IDCP. This may affect treatment. For example,
National Comprehensive Cancer Network guidelines
suggest genetic counselling or germline testing for
several oncogenes if IDCP is identified.
G R A D I N G I D C P A S S O C I A T E D W I T H I N V A S I V E
C A N C E R B U T N O T P U R E I D C P I S N O T F E A S I B L E
Both of the current authors agree on not grading
pure IDCP. However, it can be almost impossible in
some cases to determine whether a case is pure IDCP
or GS 4 + 4 = 8 on routine H&E-stained sections. If
the policy is to just group IDCP together with inva-
sive cancer and grade the entire lesion, there will be
the tendency to not distinguish IDCP from invasive
cancer with immunohistochemistry. Consequently,
there will probably be cases of pure IDCP that are
graded as GS 4 + 4 = 8 or even GS 9 if the IDCP has
necrosis. As noted above, these patients, on the basis
of such biopsy grading, will be incorrectly labelled as
having very aggressive cancer, resulting in potential
overtreatment or incorrect treatment.
L A C K O F E V I D E N C E T H A T G R A D I N G I D C P A S
I N V A S I V E C A R C I N O M A I S M O R E A C C U R A T E
P R O G N O S T I C A L L Y
In cases of GS 4 + 3 = 7 (Grade Group 3) or GS
3 + 4 = 7 (Grade Group 2) with IDCP showing come-
donecrosis, if the IDCP were included in the grade the
tumour would be GS 4 + 5 = 9 (Grade Group 5) or
© 2020 The Authors. Histopathology published by John Wiley & Sons Ltd, Histopathology, 78, 231–239.
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GS 3 + 5 = 8 (Grade Group 4), respectively. In the
more common setting, if IDCP were graded, there
would be GS 3 + 4 = 7 cases that would be upgraded
to GS 4 + 3 = 7. Currently, no compelling data exist
to support these increases in grade in these settings.
T H E S P U R I O U S C L A I M T H A T H I S T O R I C A L S T U D I E S
I N C O R P O R A T E D I D C P I N T H E G R A D E
One argument that has been proposed for grading
IDCP as if it were invasive carcinoma is that, in his-
torical studies in which grade correlated with progno-
sis, IDCP, if present, was graded as if it were invasive
carcinoma. However, in these historical studies there
would have been only a very small proportion of
prostate cancer cases for which the highest grade
would have changed if IDCP had been graded as
invasive carcinoma or not. The prognosis for this
small proportion of cases with a grade change would
not have any statistical impact on how well the high-
est grade overall in the study correlated with progno-
sis. Rather, the overall correlation of grade and
prognosis would be driven by the much larger num-
ber of cases either lacking IDCP or in which IDCP
was associated with invasive high-grade cancer.
However, whether IDCP was graded could have a sig-
nificant impact on an individual patient’s manage-
ment.
F L A W E D S T U D I E S C O N C L U D I N G T H A T G R A D I N G
I D C P I S A C C U R A T E
The same faulty logic resulting in historical studies




Figure 3. A, Representative image of a case of pure intraductal carcinoma of the prostate (IDCP) in a totally embedded radical prostatectomy
specimen. B, Higher magnification of IDCP [same case as in (A)]. C, Immunohistochemistry for basal cell markers demonstrating intact basal cells
around each gland of IDCP [same case as in (A) and (B)]. D, Pure IDCP in a large transurethral resection of the prostate specimen with extensive
IDCP and no invasive carcinoma. E, Higher magnification of IDCP [same case as in (D)]. F, Immunohistochemistry for basal cell markers
demonstrating intact basal cells around each gland of IDCP [same case as in (D) and (E)]
© 2020 The Authors. Histopathology published by John Wiley & Sons Ltd, Histopathology, 78, 231–239.
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determining how often incorporation of IDC in the
grade would change the Grade Group.20 Only cases
in which the grade would be affected by the incorpo-
ration of IDCP should be analysed to determine
whether the incorporation or exclusion of IDCP better
correlates with prognosis. In addition, some of the
contemporary studies have included cohorts of only
sextant (six cores) biopsies, which is not relevant to
current practice. IDCP sampled on sextant biopsy was
probably markedly under-represented, and therefore
its impact was minimal. Another flaw in these studies
is the use of the H&E appearance to determine
whether IDCP was present. In many cases with cribri-
form Gleason pattern 4, it is almost impossible to
determine whether there is IDCP or infiltrating cribri-
form Gleason pattern 4. Finally, some studies have
used ‘Global Grade Group’; this involves averaging all
the cancer in a case as if it were one long core and
assigning a grade on that basis, and/or combining all
of the tumour in a radical prostatectomy, as opposed
to looking at the index tumour nodule grade. Report-
ing of only the global grade makes these studies not
applicable to current practice in the USA and many
other parts of the world, where assigning a global
grade is not routine practice.
E X P E D I E N C Y I S N O T N E C E S S A R I L Y B E S T F O R
P A T I E N T C A R E
A frequent argument for including IDCP in the grade
is that one cannot reliably identify basal cells on H&E-
stained sections and, in some cases, immunohisto-
chemistry is needed to identify IDCP in order to factor
it out for grading. However, it is not necessary to per-
form basal cell immunohistochemistry on needle
biopsy and radical prostatectomy specimens to identify
IDCP if the results of the stains would not change the
overall highest GS/Grade Group for the case. This is
the situation in the vast majority of cases, as IDCP is
typically associated with overt infiltrating high-grade
cancer. In the setting of overt invasive high-grade car-
cinoma, it is reasonable to grade glands that have the
differential diagnosis of high-grade carcinoma versus
IDCP as all being invasive carcinoma. However, for
the uncommon biopsy that shows either no definite
invasive carcinoma or GS 6 cancer along with cribri-
form glands that include a differential diagnosis of
IDCP versus Gleason pattern 4 cancer, one should per-
form immunohistochemistry for basal cell markers.
The counterargument states: ‘Percentage Gleason
pattern 4 reporting is simpler if IDCP with invasive
A B
C D
Figure 4. A, Low magnification of extensive intraductal carcinoma of the prostate (IDCP) associated with a small focus of Gleason score
3 + 3 = 6 in an entirely embedded radical prostatectomy. B, Higher magnification of (A) showing cribriform glands of IDCP with necrosis
admixed with small, well-formed discrete glands of Gleason score 3 + 3 = 6. C, Low magnification of immunohistochemical staining for basal
cell markers demonstrating intact basal cells around each gland of IDCP [same case as in (A) and (B)]. D, Higher magnification of immunohis-
tochemical staining for basal cell markers demonstrating intact basal cells around each gland of IDCP and negative staining in small non-
cribriform glands of Gleason score 3 + 3 = 6 [same case as in (A) and (B)]. [Colour figure can be viewed at wileyonlinelibrary.com]
© 2020 The Authors. Histopathology published by John Wiley & Sons Ltd, Histopathology, 78, 231–239.
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carcinoma is incorporated in the GS.’ I agree that it
is simpler, but we should not determine practice pat-
terns on the basis of what is ‘simpler’. As noted
above, the GUPS recommends performing immuno-
histochemistry only in cases in which the distinction
would affect the highest GS per part for the case. In
terms of the percentage of Gleason pattern 4, the only
situation in which immunohistochemistry would
need to be performed would be if one could not dis-
tinguish between GS 3 + 4 = 7 (Grade Group 2) and
GS 4 + 3 = 7 (Grade Group 3). This is very infre-
quent. Probably the most critical aspect of reporting
the percentage of Gleason pattern 4 for Grade Group
2 is to identify patients whose cancers have a mini-
mal percentage of Gleason pattern 4, and who, in
certain circumstances, could be candidates for active
surveillance. In patients with GS 3 + 4 = 7 (Grade
Group 2), in whom the percentage of Gleason pattern
4 might vary according to whether IDC is present,
this would not be critical. For example, consider a
hypothetical case with the abnormal area consisting
of 60% Gleason pattern 3, 10% poorly formed glands,
and 30% cribriform glands, with a differential diagno-
sis of invasive Gleason pattern 4 or IDCP. If the crib-
riform glands were invasive, the diagnosis would be
GS 3 + 4 = 7 (Grade Group 2) with 40% Gleason
pattern 4. If the cribriform glands were IDCP, then
the diagnosis would be GS 3 + 4 = 7 (Grade Group
2) with 14% (10/70) Gleason pattern 4 with exten-
sive IDCP. Either diagnosis would rule out active
surveillance, either because of a greater percentage of
Gleason pattern 4 in the former situation, or the pres-
ence of IDCP in the latter situation.
In my busy consulting practice, where I see ~30
prostate cancers per day, approximately in one case
per week is it necessary to perform basal cell stains for
accurate grading. Sometimes doing what is best and
most accurate for patient care may not be the easiest
or cheapest practice, but it is critical for pathologists
not to take short cuts and sacrifice quality.
In summary, incorporating IDCP in the grade is
not based on studies specifically addressing the subset
of cases in which the grade would be affected by
including or excluding IDCP. For example, there is no
evidence, either for biopsies or for prostatectomies,
that the presence of IDCP (versus the absence) results
in prognostic difference for each individual Grade
Group (or GS). Such studies in contemporary patient
cohorts and practice are sorely needed. However, evi-
dence exists that incorporating IDCP will definitely
result in the wrong grade for a small subset of
patients with either no cancer or low-grade cancer
associated with IDCP. In practice, there is only a
small subset of cases in which the presence of IDCP
would change the grade, requiring basal cell
immunohistochemistry to be performed. By not incor-
porating IDCP in the grade, future studies in a con-
temporary practice can be performed to assess the
specific issue of whether grading IDCP or excluding it
from the grade better correlates with prognosis.
Discussion
The GUPS and the ISUP concur on the reporting of
pure IDCP, with both recommending that pure IDCP
should not be graded, and that immunohistochemistry
should be performed in such cases when no associated
invasive component is identified. There is no funda-
mental disagreement between the ISUP and the GUPS
regarding the clinical implication of IDCP associated
with invasive prostate cancer. Both agree that the pres-
ence of an IDCP component in this setting is an
adverse prognostic factor. The difference of opinion per-
tains to how this information should be conveyed to
the treating clinician. The GUPS position is that incor-
porating IDCP in the GS would risk overgrading. For
example, rare cases of biopsy GS 3 + 3 are not associ-
ated with unsampled high-grade prostate cancer.
Hence, the GUPS recommends that the presence of
IDCP be clearly documented (e.g. in the biopsy sum-
mary or in a synoptic format). Conversely, the ISUP
position is that excluding IDCP from the GS risks
undergrading, as most patients with biopsy GS 3 + 3
associated with IDCP have high-grade invasive prostate
cancer. Hence, the ISUP recommends reporting such
rare cases as GS 7 with an explanatory comment.
However, the current situation can be confusing
for clinicians. When a prostate cancer report com-
ments on the presence of associated IDCP, it may be
unclear whether or not this component has been
incorporated in the reported GS. There is a need for
international consensus on this issue.
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